A program to accelerate drug trials often provides the market with new drugs that are only marginally more effective, but ...

Federal regulators shook up the booming weight loss drug marketplace when they announced Mounjaro and Zepbound to be no ...

This summary provides the latest updates in health news, including HIV cases from organ transplants in Brazil, Sanofi's ...

Recent health news highlights include HIV transmission via organ transplants in Brazil, Sanofi discussing a sale of its ...

One of the downsides of treatments such as Ozempic or Mounjaro is that even though patients wind up losing weight, they also tend to shed muscle mass. Losing too much muscle mass can be a health risk ...

Like many health plans, Lilla’s insurance didn’t cover Wegovy for weight loss use. Out of pocket, a month’s supply came with a price tag of more than $1,300. Even after applying a coupon from the drug ...

Click in for more news from The Hill{beacon} Health Care Health Care   The Big Story Rival manufacturers fight for the right to sell weight loss drugsThere’s a new fight brewing between ...

The U.S. Food and Drug Administration on Friday agreed to reconsider its recent decision barring drug compounders from ...

The FDA updated its database of drugs in shortage to remove tirzepatide, which had sat on that list – along with related semaglutide-based drugs, Ozempic and Wegovy – since 2022 amid unprecedented ...

Peptide companies' are creating knock-off versions of these drugs that have not been approved by the FDA and contain ...

Six years ago, Sanofi gave $125 million and promised over $1 billion in milestone payments to buzzy neuroscience startup ...

There’s a war brewing over blockbuster weight loss medications — and patients are now getting caught in the crossfire.